Zoledronic acid prevents the development of myeloma bone disease and increases survival

Zoledronic acid prevents the development of myeloma bone disease and increases survival

Bibliographic Details
Main Authors:	Shipman, C, Vanderkerken, K, De Raeve, H, Perry, M, Hijzen, A, Lippitt, J, Green, J, Van Marck, E, Van Camp, B, Croucher, P
Format:	Journal article
Published:	2002

Similar Items

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
by: Croucher, P, et al.
Published: (2002)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
by: Croucher, P, et al.
Published: (2003)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
by: Croucher, P, et al.
Published: (2001)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
by: Vanderkerken, K, et al.
Published: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
by: De Leenheer, E, et al.
Published: (2004)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
by: De Leenheer, E, et al.
Published: (2002)

Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
by: Shipman, C, et al.
Published: (2000)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
by: Croucher, P, et al.
Published: (2002)

Zoledronate prevents bone loss after stroke
by: Poole, K, et al.
Published: (2006)

A single infusion of zoledronate prevents bone loss after stroke.
by: Poole, K, et al.
Published: (2007)

Single dose of zoledronate prevents bone loss after acute stroke
by: Poole, K, et al.
Published: (2006)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
by: Zhuang, J, et al.
Published: (2008)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
by: Shipman, C, et al.
Published: (2000)

The homing of prostate cancer to bone in vivo is modulated by Zoledronic acid
by: Reeves, K, et al.
Published: (2011)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
by: Jagdev, S, et al.
Published: (2001)

Advances in the management of myeloma bone disease.
by: Shipman, C, et al.
Published: (2005)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
by: Edwards, C, et al.
Published: (2007)

The effects of zoledronate on iliac bone remodelling in stroke patients
by: Poole, K, et al.
Published: (2007)

Tumor-host cell interactions in the bone disease of myeloma.
by: Fowler, J, et al.
Published: (2011)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
by: Locklin, R, et al.
Published: (2005)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
by: Mueller, G, et al.
Published: (2004)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
by: Shipman, C, et al.
Published: (2003)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
by: Mueller, G, et al.
Published: (2004)

Bone structure and remodelling in stroke patients: early effects of zoledronate.
by: Poole, K, et al.
Published: (2009)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
by: Locklin, R, et al.
Published: (2007)

Increasing adiponectin via an apolipoprotein peptide mimetic, L-4F, increases bone formation in normal mice and prevents myeloma bone disease in vivo
by: Fowler, J, et al.
Published: (2011)

Yearly zoledronic acid in postmenopausal osteoporosis.
by: Poole, K, et al.
Published: (2007)

Dkk1 modulates osteoclastogenesis and bone resorption: Implications for myeloma bone disease.
by: Oyajobi, B, et al.
Published: (2005)

Anti-tumour activity of bisphosphonates in human myeloma cells.
by: Shipman, C, et al.
Published: (1998)

A single injection of zoledronic acid may prevent bone loss after stroke: Planned interim analysis of a randomised trial
by: Poole, K, et al.
Published: (2004)

The effects of zoledronate on iliac bone remodelling; a histomorphometric study in stroke patients
by: Poole, K, et al.
Published: (2007)